{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:24:47Z","timestamp":1792448687247,"version":"4.5.0"},"reference-count":35,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011447","name":"Science and Technology Department of Henan Province","doi-asserted-by":"crossref","award":["112102310306"],"award-info":[{"award-number":["112102310306"]}],"id":[{"id":"10.13039\/501100011447","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec007\">\n<jats:title>Background<\/jats:title>\n<jats:p>Baricitinib is an oral selective inhibitor of Janus kinase 1\/2 that has achieved clinically meaningful outcomes for systemic lupus erythematosus (SLE). Only two phase 3 randomized clinical trials (SLE-BRAVE-I and SLE-BRAVE-II) have been completed, but their conclusions were inconsistent. We aimed to determine the efficacy and safety of once-daily oral baricitinib 4\u2009mg or 2\u2009mg treatment versus placebo in participants with active SLE.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec008\">\n<jats:title>Methods<\/jats:title>\n<jats:p>SLE-BRAVE-I and SLE-BRAVE-II are two multicenter, placebo-controlled, double-blind, phase 3 randomized clinical trials with follow-up to 52 weeks. At baseline, 1535 patients (aged \u226518 years) with active SLE (excluding those with central nervous system and severe active renal disease) receiving stable background therapy were randomly assigned 1:1:1 to baricitinib 4\u2009mg, baricitinib 2\u2009mg, or placebo once daily for 52 weeks. The primary endpoint was the proportion of patients with an SLE Responder Index (SRI)-4 response at week 52 in the baricitinib 4\u2009mg treatment group compared with placebo.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec009\">\n<jats:title>Results<\/jats:title>\n<jats:p>There was no difference in the primary efficacy outcome of the proportion of SRI-4 responders at week 52 between participants who received baricitinib 4mg (263 [52%]; odds ratio (OR) 1.27 [95% CI 0.99, 1.63]), 2\u2009mg (246 [48%]; 1.09 [0.85, 1.39]) and placebo (232 [46%]). However, based on SLE-BRAVE-I and SLE-BRAVE-II studies, baricitinib 4\u2009mg and baricitinib 2\u2009mg were more effective in reducing the disease activity in participants who treated with a glucocorticoid dose at baseline of 10\u2009mg per day or higher of prednisone or equivalent, and baricitinib 4\u2009mg was more effective in reducing the disease activity in participants with highly active disease (SLEDAI-2K score at baseline &gt;10). None of the major secondary endpoints, including time to first severe flare and glucocorticoid tapering, were met. Compared with placebo, baricitinib 4\u2009mg and baricitinib 2\u2009mg in the treatment of SLE did not increase the incidence of treatment-emergent adverse events (TEAEs).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec010\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Pooled analysis showed that once-daily oral baricitinib 4\u2009mg or baricitinib 2\u2009mg in addition to SOC did not reduce the overall disease activity compared with placebo although they were safe for SLE. However, baricitinib might be a potential treatment option for SLE in certain subpopulation, such as in participants who received a glucocorticoid dose at baseline of 10\u2009mg per day or higher of prednisone or equivalent (baricitinib 4\u2009mg and baricitinib 2\u2009mg) and in participants with highly active disease (SLEDAI-2K score at baseline &gt;10) (baricitinib 4\u2009mg).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec011\">\n<jats:title>Trial registration number<\/jats:title>\n<jats:p>ClinicalTrials. gov Registry (NCT03616912 and NCT03616964).<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0320179","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T18:04:24Z","timestamp":1746813864000},"page":"e0320179","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["Clinical outcomes of baricitinib in patients with systemic lupus erythematosus: Pooled analysis of SLE-BRAVE-I and SLE-BRAVE-II trials"],"prefix":"10.1371","volume":"20","author":[{"given":"Juntao","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yantao","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3472-4784","authenticated-orcid":true,"given":"Changjiang","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"issue":"12","key":"pone.0320179.ref001","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/nrrheum.2016.186","article-title":"New insights into the immunopathogenesis of systemic lupus erythematosus","volume":"12","author":"GC Tsokos","year":"2016","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"pone.0320179.ref002","doi-asserted-by":"crossref","first-page":"103537","DOI":"10.1016\/j.isci.2021.103537","article-title":"DOCK8-expressing T follicular helper cells newly generated beyond self-organized criticality cause systemic lupus erythematosus","volume":"25","author":"S Shiozawa","year":"2022","journal-title":"iScience"},{"issue":"13","key":"pone.0320179.ref003","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and management of rheumatoid arthritis: a review","volume":"320","author":"D Aletaha","year":"2018","journal-title":"JAMA"},{"issue":"2","key":"pone.0320179.ref004","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/rheumatology\/kex412","article-title":"Unchanging premature mortality trends in systemic lupus erythematosus: a general population-based study (1999-2014)","volume":"57","author":"AM Jorge","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"pone.0320179.ref005","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13075-022-02756-3","article-title":"\u201cNot at target\u201d: prevalence and consequences of inadequate disease control in systemic lupus erythematosus-a multinational observational cohort study","volume":"24","author":"R Kandane-Rathnayake","year":"2022","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"pone.0320179.ref006","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/art.40512","article-title":"Brief report: lupus-an unrecognized leading cause of death in young females: a population-based study using nationwide death certificates, 2000-2015","volume":"70","author":"EY Yen","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"9767","key":"pone.0320179.ref007","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"SV Navarra","year":"2011","journal-title":"Lancet"},{"issue":"8","key":"pone.0320179.ref008","doi-asserted-by":"crossref","first-page":"e595","DOI":"10.1016\/S2665-9913(21)00119-3","article-title":"Clinician-reported outcome measures in lupus trials: a problem worth solving","volume":"3","author":"K Connelly","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"6","key":"pone.0320179.ref009","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"A Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"pone.0320179.ref010","first-page":"CD010668","article-title":"Belimumab for systemic lupus erythematosus","volume":"2","author":"JA Singh","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"9894","key":"pone.0320179.ref011","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(13)60954-X","article-title":"Immunopathogenic mechanisms of systemic autoimmune disease","volume":"382","author":"M Wahren-Herlenius","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"pone.0320179.ref012","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/1535370218824547","article-title":"IL-12 and IL-23\/Th17 axis in systemic lupus erythematosus","volume":"244","author":"M Larosa","year":"2019","journal-title":"Exp Biol Med (Maywood)"},{"issue":"1","key":"pone.0320179.ref013","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13075-022-02794-x","article-title":"Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial","volume":"24","author":"T D\u00f6rner","year":"2022","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"pone.0320179.ref014","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/art.39950","article-title":"Gene Expression and pharmacodynamic changes in 1,760 systemic lupus erythematosus patients from two phase III trials of BAFF blockade with tabalumab","volume":"69","author":"RW Hoffman","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"pone.0320179.ref015","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"DM Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"issue":"0 2","key":"pone.0320179.ref016","doi-asserted-by":"crossref","first-page":"ii111","DOI":"10.1136\/annrheumdis-2012-202576","article-title":"Janus kinase inhibitors in autoimmune diseases","author":"JJ O\u2019Shea","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"18","key":"pone.0320179.ref017","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","article-title":"Two phase 3 trials of baricitinib for alopecia areata","volume":"386","author":"B King","year":"2022","journal-title":"N Engl J Med"},{"issue":"10143","key":"pone.0320179.ref018","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"392","author":"DJ Wallace","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"pone.0320179.ref019","doi-asserted-by":"crossref","first-page":"e000424","DOI":"10.1136\/lupus-2020-000424","article-title":"Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways","volume":"7","author":"T D\u00f6rner","year":"2020","journal-title":"Lupus Sci Med"},{"issue":"9","key":"pone.0320179.ref020","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1136\/annrheumdis-2022-222335","article-title":"Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus","volume":"81","author":"T D\u00f6rner","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"10381","key":"pone.0320179.ref021","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0140-6736(22)02607-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)","volume":"401","author":"EF Morand","year":"2023","journal-title":"Lancet"},{"issue":"10381","key":"pone.0320179.ref022","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(22)02546-6","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)","volume":"401","author":"M Petri","year":"2023","journal-title":"Lancet"},{"issue":"9","key":"pone.0320179.ref023","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"MC Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"11","key":"pone.0320179.ref024","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/art.1780251101","article-title":"The 1982 revised criteria for the classification of systemic lupus erythematosus","volume":"25","author":"EM Tan","year":"1982","journal-title":"Arthritis Rheum"},{"issue":"2","key":"pone.0320179.ref025","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1016\/S2665-9913(19)30037-2","article-title":"Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study","volume":"1","author":"V Golder","year":"2019","journal-title":"Lancet Rheumatol"},{"issue":"23","key":"pone.0320179.ref026","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1056\/NEJMoa2306691","article-title":"Baricitinib and \u03b2-cell function in patients with new-onset type 1 diabetes","volume":"389","author":"M Waibel","year":"2023","journal-title":"N Engl J Med"},{"issue":"10401","key":"pone.0320179.ref027","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(23)00921-2","article-title":"Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial","volume":"402","author":"AV Ramanan","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"pone.0320179.ref028","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41584-023-01062-9","article-title":"Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician","volume":"20","author":"Z Szekanecz","year":"2024","journal-title":"Nat Rev Rheumatol"},{"issue":"10373","key":"pone.0320179.ref029","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0140-6736(22)02036-0","article-title":"Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study","volume":"401","author":"S Verstovsek","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"pone.0320179.ref030","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach","volume":"18","author":"Y Tanaka","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"21","key":"pone.0320179.ref031","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib induction and maintenance therapy for crohn\u2019s disease","volume":"388","author":"EV Loftus","year":"2023","journal-title":"N Engl J Med"},{"issue":"7","key":"pone.0320179.ref032","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1080\/1744666X.2019.1608821","article-title":"Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update","volume":"15","author":"S Kubo","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"issue":"12","key":"pone.0320179.ref033","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nrrheum.2012.184","article-title":"Coagulation and the fibrin network in rheumatic disease: a role beyond haemostasis","volume":"8","author":"B Hoppe","year":"2012","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"pone.0320179.ref034","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"R Furie","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"pone.0320179.ref035","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"EF Morand","year":"2020","journal-title":"N Engl J Med"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0320179","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T18:04:32Z","timestamp":1746813872000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0320179"}},"subtitle":[],"editor":[{"given":"Vipula Rasanga","family":"Bataduwaarachchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0320179","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]}}}